Allarity Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the Securities and Exchange Commission on November 13, 2026, reporting a net loss of $12.355 million for the nine months ended September 30, 2026.
Key Highlights
- Nine-month net loss: The company reported a net loss of $12.355 million for the nine months ended September 30, 2026, compared to a net loss of $7.858 million for the same period in 2025, according to the filing.
- Q3 net loss: For the three months ended September 30, 2026, the company reported a net loss of $6.200 million, versus $2.806 million in Q3 2025.
- Research and development expenses: R&D expenses for the nine months ended September 30, 2026 were $6.861 million, up from $4.927 million for the same period in 2025.
- Cash position: As of September 30, 2026, the company held $14.092 million in cash and $9.998 million in restricted cash, per the balance sheet.
- Stockholders' equity deficit: Total stockholders' equity was $(2.262) million at September 30, 2026, compared to positive $9.828 million at December 31, 2025.
- Shares outstanding: As of November 12, 2026, there were 15,997,108 shares of common stock outstanding, as stated on the cover page of the filing.
- License revenue: The company recorded $30,000 in total license revenue for the nine months ended September 30, 2026, compared to no revenue in the same period of 2025.
Allarity Therapeutics Reports Widening Losses and Increased R&D Spending Through September 2026
Allarity Therapeutics, Inc. (NASDAQ:ALLR), a clinical-stage biopharmaceutical company, disclosed its unaudited condensed consolidated financial results for the three and nine months ended September 30, 2026. According to the filing, total operating expenses for the nine-month period reached $10.896 million, up from $9.687 million in the first nine months of 2025, driven primarily by higher research and development costs.
The filing shows that R&D expenses for the nine months ended September 30, 2026 were $6.861 million, compared to $4.927 million for the same period in 2025. General and administrative expenses declined to $4.035 million from $4.760 million over the same comparison period. The company reported interest expense of $1.960 million for the nine months ended September 30, 2026, versus $126,000 in the prior-year period, a change the filing attributes in part to promissory note obligations reflected on the balance sheet.
As of September 30, 2026, the company's balance sheet showed total assets of $27.220 million and total liabilities of $29.482 million, resulting in a stockholders' equity deficit of $2.262 million. The balance sheet includes a promissory note, net of discounts and accrued interest, of $21.584 million as a current liability, which was not present at December 31, 2025. The accumulated deficit stood at $142.552 million as of September 30, 2026, compared to $130.197 million at December 31, 2025. The company also disclosed that its shares are classified under smaller reporting company and emerging growth company designations, as indicated on the cover page. The filing notes that forward-looking statements are subject to risks and uncertainties described in the company's Annual Report on Form 10-K filed on March 30, 2026.
What Was Disclosed
Allarity Therapeutics filed its quarterly report for the period ended September 30, 2026, disclosing a nine-month net loss of $12.355 million, increased R&D spending, a stockholders' equity deficit of $2.262 million, and the addition of a $21.584 million promissory note as a current liability.



Please wait processing your request...